At a glance
This program funds one cooperative agreement to support a national Hereditary Hemorrhagic Telangiectasia center. The center must work with at least 15 clinical centers, support a patient data registry, pilot EHR alert and data-transfer improvements, provide provider education, and coordinate quality improvement and patient engagement activities. Eligible applicants are domestic state governments and other domestic organizations; individuals are not eligible. The total funding available in FY 2026 is $2,900,000, with one award of up to $2,900,000 for a project period from 09/01/2026 to 08/31/2029. There is no cost-sharing requirement, and applications must come from a domestic entity in the 50 states, D.C., or specified U.S. territories and freely associated states.
What it funds
Official description from grants.gov
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Who can apply
- State governments
- Unrestricted